In early December 2004, the FDA Advisory Board held a conference to review the clinical trial data on Procter & Gamble's testosterone patch, called Intrinsat. The FDA reviewed two trials in surgically menopausal women and submitted for efficacy. Two of the trials in naturally menopausal women, submitted for safety, were of 6 and 12 months, with extension data to 18 months. The FDA voted unanimously to request the gathering more longterm safety data. The full FDA regulatory committee did not vote on the issue as Proctor & Gamble withdrew the drug from further consideration. This is an unfortunate decision for various reasons. The most important result of a favorable decision would go much further than just approving another treatment modality. We have lost the opportunity of having a country and a regulatory agency validate the concept and diagnosis of androgen deficiency in women. This could have facilitated requests for research funding in this area, and made androgen deficiency a valid topic for evaluation, even though many doctors have been treating it off-label for decades. More research is needed to define more precisely the significance of a low testosterone level in women, not unlike the debate regarding male patients. Some people with negative feelings toward the idea of women receiving testosterone predicted its widespread use and even abuse. The clinical trials and projected use were strictly for replacement in menopausal women whose levels went below a normal therapeutic range as compared to young women, a formula that is widespread when dealing with normal male levels of testosterone.
Women produce androgens from two organs, the ovaries and the adrenal glands, as opposed to the vast majority of testosterone produced in the male testicle. At menopause, or a few years thereafter, the ovarian production of androgens ceases. This loss of half of a woman's androgen production is coupled with the decreased production of adrenal androgens that commences in the 20's, with the result that shortly after menopause women may have lost 75% of their androgen production.
The symptoms of androgen deficiency in women are similar to those seen in men, decreased libido, decreased energy and decreased sense of well being. Women often present with decreased lubrication, even when adequately estrogenized. Muscle function and bone metabolism may also be seen in both sexes. Decreased arousability is also seen in women with androgen deficiency. Decreased sexual desire is certainly a hallmark symptom, and can also be a prominent symptom in depression and other condition such as acute and chronic illness, medication, relationship problems, etc. It is the duty of the evaluating health-care professional to rule out these conditions, realizing, of course, that many women may have more than one cause of decreased libido.
The request for more safety data is never to be faulted. You can never have enough safety data. Of course, there really are no long-term safety data in many areas concerning men on testosterone replacement, the exception being prostate abnormalities.
In the six months exposure with the 2200 women in the Phase III studies, one would expect that any problems with hirsuitism, acne or hirsuitism would be seen during this time frame. The fear that testosterone would be aromatized to estrogen is more paranoia than reality. The amount of testosterone converted to estrone or estradiol has been shown to be low, making any risk of breast cancer extremely unlikely. Even the Million Women Study in the UK on the effect of hormone replacement therapy on breast cancer had serious design flaws. The study showed a slight risk of breast cancer, but there are several problems with the design of the study, including a significant recruitment bias.
The HERS and WHI studies that showed a slight increase in vascular disease with conjugated estrogen and synthetic progesterone were severely flawed. The HERS study found an increase in vascular events in women who had already had had vascular events. The WHI study found increased vascular events in a general population of menopausal women, but the mean duration of menopause of the women entering the study was 12 y, almost predisposing the study to failure as estrogen therapy is felt to be preventative and not reparative. Very recent studies in younger women have suggested a protective effect of hormone replacement therapy. There are those who also feel that a strong synthetic progestin, like medroxyprogesterone acetate, may nullify any good effect of estrogen on the vascular endothelium. The WHI study using estrogen alone in hysterectomized women, although showing a very small increase in stroke, showed a decrease in breast cancer, and no increase in cardiac disease.
Apart from the issues raised above, which are valid concerns and should be debated, there may have been some bad timing and political pressures brought to bear on the decision not to accept the current data on the female testosterone patch. Congress has been quite concerned with the withdrawal of Vioxxt and other drugs from the market because of deaths felt to be related to the use of these drugs. Questions have been raised about the inability to detect defects in medicines studied under FDA-accepted protocols resulting in serious morbidity and mortality. An obvious conclusion is that more and longer-term safety data may be required before drugs are released into the marketplace. Unfortunately, the fact that testosterone is a natural compound and not a drug foreign to the body does not seem to enter into this equation. In this context, the request for more safety data cannot be unexpected. Also, testosterone has been given to postmenopausal women for decades, albeit off-label, with no serious safety problems being discovered. The problem is that there are no long-term safety studies. Long-term data are also wanting in men, and a recent study has shown safety data in men on testosterone therapy up to 42 months, where the majority completed only 36 months.
Hopefully, the further data required will be reasonable and we will be able to look forward to treat postmenopausal women who have androgen deficiency with a reliable product. This will help to open up a new era of treatment in female sexual dysfunction.
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